RCT: No benefit from antithrombotic therapy (aspirin or apixab | Critical Care & Emergencies

RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19.

https://www.linksmedicus.com/news/rct-no-benefit-antithrombotic-therapy-aspirin-apixaban-outpatients-clinically-stable-symptomatic-covid-19/